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INTRODUCTION
Idiopathic hypereosinophilic syndrome (HES) is character-
ized by persistent blood and tissue eosinophilia. HES involves 
multiple organ systems, predominantly the skin, heart, lung, 
gastrointestinal tract, and nervous system.
1 Often, the present-
ing manifestation is thrombosis. Sporadic cases of intra-abdom-
inal, cerebral, and cutaneous thrombosis have been reported.
2 
Disseminated intravascular coagulation (DIC) associated with 
HES is rare, and few cases have been reported.
3-6 Here we re-
port a unique case of HES presenting with pulmonary, renal, 
splenic, and intracerebral thrombosis associated with DIC.
CASE REPORT
A 23-year-old woman was referred to the emergency depart-
ment of our hospital with fever and hemoptysis. She had bilat-
eral costovertebral angle tenderness. A simple chest X-ray dem-
onstrated patchy consolidation on the right middle lobe and 
peribronchial opacity on the lower bilateral lung fields (Fig. 1A). 
A chest computed tomography (CT) scan revealed a heavy bur-
den of pulmonary embolism in the bilateral pulmonary arteries 
and their branches, with bland infarction in both lungs (Fig. 1B-
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D). In an abdominal-pelvic CT scan to evaluate the patient’s 
flank pain, a focal wedge-shaped low-density lesion in the right 
kidney midpole and spleen was found (Fig. 2), suggesting in-
farction. A duplex ultrasonogram of the lower extremities for 
the edematous right lower leg revealed a totally occluding 
thrombus of the right femoropopliteal vein and a partially oc-
cluding thrombus of the right posterior tibial vein.
White blood cell count was elevated (11,430/μL) with 21% eo-
sinophils (2,550/μL), hemoglobin 11 g/dL, and thrombocyto-
penia of 39,000/μL. The prothrombin time (PT) was prolonged 
to 15 seconds and activated partial thromboplastin time was 42 
seconds. Fibrinogen was in the normal range (156 mg/dL), but 
D-dimer was increased to 46.14 μg/mL. Total IgE was 2,296 IU/
mL and ECP was 78.6 ng/mL. Anti-neutrophil cytoplasmic and 
cardiolipin antibodies were negative. A test for parasites in the 
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stool and serum was negative. A bone marrow biopsy showed 
normal cellularity with increased eosinophils. Fip1-like1 and 
platelet-derived growth factor receptor alpha gene (FIP1L1-
PDGFRA) fusion was not detected. An echocardiogram showed 
no abnormal findings.
She was diagnosed as idiopathic HES manifested as multiple 
thromboembolisms involving the lung, kidney, spleen, and 
lower extremities. She was treated with corticosteroids (methyl-
prednisolone 1 mg/kg) and heparin on the second day of ad-
mission. Eosinophil count normalized within 3 days. On the 
fifth day of treatment, she complained of a persistent and wors-
ening headache. A brain CT scan revealed left frontal and tem-
poral lobe intracerebral hemorrhage. D-dimer remained ele-
vated at 18.93 μg/mL, and the platelet count was low at 30,000/
μL. Due to suspicion of hemorrhage associated with intracere-
bral thrombosis, we continued corticosteroid and anticoagula-
tion therapy. On the ninth day of treatment, a follow-up brain 
CT scan showed no interval change of hemorrhage. Although 
the peripheral eosinophil count was within the normal range, 
thrombocytopenia (48,000/μL) and D-dimer elevation (60 μg/
mL) remained abnormal. We started subcutaneous injection of 
interferon-alpha (INF-α) (3 MU/day), after which the thrombo-
cytopenia and elevation of D-dimer gradually normalized (Fig. 
3). The patient’s headache and abdominal pain were then com-
pletely absent. INF-α injections were stopped after 5 days and 
corticosteroids were gradually tapered off without any recur-
rence of symptoms or abnormal laboratory findings. 
DISCUSSION
Since 1975, three criteria have been used to define HES: blood 
eosinophilia >1,500/μL for longer than 6 months; lack of evi-
dence of parasitic, allergic, or other known causes of eosinophil-
ia; and presumptive signs of organ involvement.
7 Our case ful-
filled the diagnostic criteria of HES with the exception of dura-
tion. However, the relative importance of HES duration is con-
Fig. 1. Chest x-ray showed patchy consolidation on the right middle lobe 
and increased peribronchial opacity on lower bilateral lung fields (A). Chest 
CT showed large thrombus (arrows) in the right interlobar artery (B) and 
combined pulmonary infarction (arrowhead) (C). Another thrombus (arrows) 
was seen in the left interlobar artery (D).
A
B
C
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troversial. Simon et al.
8 emphasized the importance of effective 
therapies to halt progression of organ damage that can occur 
with HES, rather than waiting if the criterion of duration has not 
been met.
The patient initially presented with pulmonary, renal, and 
splenic infarctions associated with eosinophilia and consump-
tive coagulopathy. Consumptive coagulopathy, also called DIC, 
is characterized by abnormal activation and consumption of 
clotting factors. Thromboembolism is one of the most serious 
complications of HES. About 25% of HES patients develop 
thromboembolism, and 5%-10% die as a result.
2 The mecha-
nisms underlying the thrombotic diathesis in HES are not fully 
understood, but the four main granule proteins released by eo-
sinophils-major basic protein (MBP), eosinophil derived neu-
rotoxin (EDN), eosinophil cationic protein (ECP), and eosino-
phil peroxidase (EPO)-are thought to cause hypercoagulation. 
ECP has been reported to promote coagulation through a fac-
tor XII-dependent mechanism.
9 MBP and EPO are known to 
activate platelets.
10 MBP can inhibit the anticoagulant activities 
of the endothelial membrane by binding to thrombomodu-
lin.
11,12 Moreover, hypothiocyanous acid (HOSCN), the predom-
inant oxidant product of EPO, has been shown to stimulate tis-
sue factor expression, thus promoting thrombosis.
13
Corticosteroids are the first-line therapy for FIP1L1-PDGFRA-
negative HES, and are very effective for reducing peripheral eo-
Fig. 2. Abdominal-pelvic CT scan showed focal wedge shaped low density lesion (arrows) in the right kidney midpole (A, C) and spleen (B) suggesting infarctions.
A
C B
Fig. 3. Disseminated intravascular coagulation profiles according to the patient 
progress. Platelet count, D-dimer, and fibrinogen level were gradually recovered 
after addition of interferon-alpha. *Gray bar, the duration of corticosteroid treat-
ment; yellow bar, the duration of interferon-alpha treatment; INF-α, interferon-
alpha; HD, hospital day.
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sinophils.
14 If corticosteroid-resistance is observed, second-line 
therapies such as INF-α, hydroxyurea, and anti-IL-5 monoclo-
nal antibodies are warranted. In this case, peripheral eosinophil 
counts were normalized immediately by corticosteroid admin-
istration. However, the consumptive coagulopathy was not cor-
rected, and intracranial hemorrhage developed, which must 
have been related to thrombosis. Peripheral eosinophil count 
does not always parallel tissue damage. Kobayashi et al.
15 re-
ported a case of idiopathic HES manifesting as acute abdomi-
nal pain caused by thrombosis of the mesenteric arteries. Al-
though the peripheral eosinophilia was profoundly reduced by 
corticosteroid administration, the patient needed emergency 
laparotomy for the intestinal perforation. There is another re-
port of progressive ischemia in the extremities with HES requir-
ing amputation of the legs, despite the use of corticosteroids.
16
In our case, administration of INF-α resulted in a restoration 
of platelet count and a decreased D-dimer level. INF-α is effec-
tive for treatment of corticosteroid-resistant HES.
17-20
In summary, the case we present here shows that activated 
eosinophils can provoke thromboembolism in various organs 
in HES. If consumptive coagulopathy is not controlled by ad-
ministration of corticosteroids alone, addition of an immuno-
modulatory therapy, such as INF-α, should be considered.
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